… Pulmonary fibrosis is the end stage of several diffuse parenchymal lung diseases (DPLDs), …
The most common form of pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), is a …

… In animal models of pulmonary fibrosis, nintedanib has demonstrated anti-fibrotic effects
including reductions in lung collagen content and morphometric fibrosis scores and reduced …

… comprises a much more diverse group, commonly distinguished from LS by insidious onset,
slow progression and a higher risk of developing chronic disease and pulmonary fibrosis. …

… remodeling in pulmonary fibrosis is also crucial for uncovering novel therapeutic targets and
… In spite of some progress made to understand the development of severe pulmonary fibrosis…

… pulmonary fibrosis via activation of growth factors, such as TGF-β1 [Citation16]. … target many
of the mediators and signaling pathways involved in the pathogenesis of pulmonary fibrosis. …

… In this review, we describe how genomic technologies have shaped our study of idiopathic
pulmonary fibrosis (IPF), a devastating, progressive scarring of the lung parenchyma, a …

… pulmonary fibrosis (IPF) is a subset of pulmonary fibrosis in which the underlying factors
causing lung tissue fibrosis … Results of the study suggested miR-26a as a novel target for IPF pre…

… pulmonary medicine remains elucidating the pathogenesis of idiopathic pulmonary fibrosis
(… The diagnosis of IPF has been a moving target, and we are still without a gold standard. The …

… Research into idiopathic pulmonary fibrosis (IPF) has been rapidly gathering pace over
the past few years. This has been driven by a number of important factors, including the …

… studies for the treatment of idiopathic pulmonary fibrosis (IPF). The most likely scenarios
are: ‘low proximity to SoC’: (1) Different target mechanisms might provide a greater window to …